pioglitazone has been researched along with Autoimmune Thrombocytopenia in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kasono, K | 1 |
| Nishida, J | 1 |
| Tamemoto, H | 1 |
| Fudaka, K | 1 |
| Namai, K | 1 |
| Kajio, H | 1 |
| Masatoshi, K | 1 |
| Kanazawa, Y | 1 |
| Kawakami, M | 1 |
1 other study available for pioglitazone and Autoimmune Thrombocytopenia
| Article | Year |
|---|---|
Thiazolidinediones increase the number of platelets in immune thrombocytopenic purpura mice via inhibition of phagocytic activity of the reticulo-endothelial system.
Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Autoantibodies; Blood Platelets; COS Cells; Disease M | 2002 |